With few treat­ment op­tions for Omi­cron, con­va­les­cent plas­ma is ready for a come­back — will the FDA be on board with out­pa­tient use?

New re­search from Johns Hop­kins shows con­va­les­cent plas­ma may work in the out­pa­tient space, which could be key as the Omi­cron vari­ant has ex­tin­guished sev­er­al mon­o­clon­al an­ti­body treat­ments.

The re­sults of this place­bo-con­trolled, mul­ti­cen­ter tri­al led by Hop­kins re­searchers showed that con­va­les­cent plas­ma re­duced the need for hos­pi­tal­iza­tion among more than 1,000 out­pa­tients with Covid-19 who par­tic­i­pat­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER